NCT05458219 2025-11-10
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Recruiting
Clinical Trials
9 trialsNCT05482893 2025-11-04
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT03941093 2024-11-05
LAPIS
Kyntra Bio
Phase 3 Completed
NCT04589234 2024-04-24
Saltikva for Metastatic Pancreatic Cancer
Salspera LLC
Phase 2 Active not recruiting
NCT04431258 2024-03-18
PanC-ASAP
Ability Pharmaceuticals SL
Phase 1/2 Completed
NCT04990037 2023-06-29
CAPAFOUR
Cantargia AB
Phase 1 Completed
NCT03504423 2023-01-03
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Cornerstone Pharmaceuticals
Phase 3 Completed
NCT01676259 2021-07-02
PROTACT
Silenseed Ltd
Phase 2 Unknown
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated